JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Molecular Pathways and Therapeutic Advances in Ischemic Heart Diseases

Rohan Kurabet*[1], S. K. Nimbal[2]

[1] *Research Scholar, PG Scholar, Department of Pharmacology, KLE College of Pharmacy (A constituent unit of KLE Academy of Higher Education and Research, Belagavi), Hubbali, Karnataka, India*
[2] *Professor and HOD, PG Scholar, Department of Pharmacology, KLE College of Pharmacy (A constituent unit of KLE Academy of Higher Education and Research, Belagavi), Hubbali, Karnataka, India*

Publication history: Received on 22nd Mar 2025; Revised on 9th April 2025; Accepted on 17th April 2025

Article DOI: 10.69613/9944w265

Abstract: Ischemic heart disease (IHD) remains the predominant cause of global mortality, characterized by diminished cardiac blood supply and often complicated by ischemia-reperfusion injury during therapeutic interventions. While myocardial reperfusion is vital for restoring circulation, it paradoxically can amplify tissue damage. Recent scientific advances have illuminated multiple cardioprotective pathways that mitigate such injury. Notable among these are ischemic preconditioning and postconditioning, which activate crucial survival cascades including PI3K/Akt and MAPK pathways. Molecular mediators such as sirtuins, HIF-1α, and autophagy-related mechanisms play vital roles in maintaining mitochondrial function and diminishing oxidative stress. The interplay between reactive oxygen species and antioxidant defenses significantly influences cardiac injury outcomes. Pharmacological interventions, particularly statins, ACE inhibitors, beta-blockers, and antiplatelet agents, demonstrate substantial cardioprotective effects through their anti-inflammatory, anti-apoptotic, and endothelial-stabilizing properties. Emerging gene therapies target specific molecular pathways to enhance cardiac resilience. Non-pharmacological approaches, including structured exercise programs, Mediterranean dietary patterns, stress reduction techniques, smoking cessation, and weight management, have proven effective in preventing disease onset and progression. The successful prevention and treatment of IHD needs a combined approach of pharmacological interventions with lifestyle modifications.

Keywords: Ischemic Heart Disease; Molecular Cardioprotection; Ischemic Preconditioning; Oxidative Stress; Therapeutic Management.

1. Introduction

Ischemic heart disease (IHD) maintains its position as the leading cause of mortality worldwide, affecting populations across socioeconomic spectrums in both developed and developing nations [1]. The standard therapeutic approach - restoration of blood flow through myocardial reperfusion - while essential, can paradoxically trigger additional complications. When blood flow suddenly returns after a period of blockage, the resultant surge of oxygen can disrupt cellular ionic homeostasis, potentially exacerbating myocardial damage [2]. Longitudinal studies have revealed that survival outcomes in IHD patients are predominantly influenced by the extent of arterial occlusion and left ventricular functional efficiency, rather than initial symptomatic presentation alone [3]. The pathogenesis of cardiovascular disease represents an intricate interplay between lifestyle patterns, environmental exposures, and genetic predispositions. Current risk prediction models, including the widely implemented ESC SCORE2, often inadequately account for genetic contributions to disease development [4].

The prevalence of IHD among patients preparing for major non-cardiac surgical procedures is substantial, with approximately 45% of U.S. veterans undergoing moderate to high-risk procedures exhibiting IHD [5]. Moreover, a significant correlation exists between IHD and peripheral arterial disease, with 40-60% of patients diagnosed with peripheral arterial disease also manifesting ischemic heart disease [6]. Recent molecular studies have identified several crucial pathways involved in cardioprotection, including the PI3K/Akt signaling cascade, mitogen-activated protein kinases (MAPK), and various cellular stress response mechanisms [7]. These pathways operate in concert with endogenous protective mechanisms such as ischemic preconditioning and postconditioning, offering potential therapeutic targets [8]. The scope of cardioprotective strategies has expanded beyond traditional pharmacological interventions to encompass genetic approaches and lifestyle modifications. Novel therapeutic modalities targeting specific molecular pathways have emerged, while the importance of preventive measures through lifestyle adjustments has gained increased recognition [9]. This review discusses about the molecular mechanisms, pharmacological interventions, and lifestyle modifications, providing a foundation for enhanced therapeutic strategies in IHD management.

* Corresponding author: Rohan Kurabet

2. Mechanisms of Cardioprotection

2.1. Ischemic Preconditioning and Postconditioning

2.1.1. Ischemic Preconditioning

Ischemic preconditioning (IPC) represents a powerful endogenous cardioprotective mechanism wherein brief, non-lethal episodes of ischemia render the myocardium more resistant to subsequent prolonged ischemic injury [10]. The molecular cascade initiated during IPC involves multiple receptor-mediated pathways, primarily triggered by adenosine, bradykinin, and opioids, converging on protein kinase C activation [11]. This activation serves as a critical mediator in establishing the sustained protective effect of IPC.

The cardioprotective mechanism of IPC operates through two distinct temporal windows. The early phase, occurring immediately after the preconditioning stimulus, involves rapid post-translational modification of existing proteins [12]. During this phase, the activation of G-protein-coupled receptors initiates a complex signaling cascade involving ERK1/ERK2 and PI3K-AKT pathways [13]. These pathways culminate in the opening of mitochondrial ATP-sensitive potassium channels, leading to controlled reactive oxygen species (ROS) generation [14].

The late phase of preconditioning, also known as the second window of protection (SWOP), emerges 24-72 hours after the initial stimulus and provides more sustained protection through the induction of cardioprotective gene expression [15]. This phase involves the upregulation of several protective proteins, including inducible nitric oxide synthase (iNOS), manganese superoxide dismutase (MnSOD), heat shock proteins, and cyclooxygenase-2 (COX-2) [16].



Figure 1. Mechanisms of Cardioprotection

2.1.2. Ischemic Postconditioning

Ischemic postconditioning (PostC) represents a clinically applicable cardioprotective strategy implemented at the onset of reperfusion [17]. The concept, first introduced by Vinten-Johansen's group, definitively established the contribution of reperfusion injury to final infarct size [18]. PostC shares several mechanistic elements with IPC, including the release of autacoids and activation of G-protein-coupled receptors [19].

A primary mechanism of PostC involves the prevention of mitochondrial permeability transition pore (MPTP) opening during early reperfusion [20]. This effect is mediated through the activation of survival kinases, particularly the PI3K-AKT and ERK1/2 pathways [21]. PostC also modulates various aspects of reperfusion injury, including reducing neutrophil accumulation, oxidative stress, and mitochondrial calcium overload [22].

2.2. Molecular Signaling Pathways

2.2.1. PI3K/Akt Pathway

The phosphoinositide 3-kinase (PI3K)/Akt signaling cascade represents a fundamental pathway in cardiac cell survival and function [23]. Upon activation, this pathway phosphorylates numerous downstream targets, including glycogen synthase kinase-3β (GSK-3β), which plays a crucial role in MPTP regulation [24]. The cardioprotective effects of PI3K/Akt signaling extend beyond acute cell survival, encompassing the regulation of cellular metabolism, protein synthesis, and anti-inflammatory responses [25]

2.2.2. MAPK Pathway

The Mitogen-Activated Protein Kinase (MAPK) family represents a complex network of signaling cascades that mediate cellular responses to various stimuli [26]. In cardiac tissue, three major MAPK subfamilies - ERK1/2, JNK, and p38 MAPK - exhibit distinct roles in cardioprotection [27]. The ERK1/2 pathway primarily promotes cell survival and growth, while JNK and p38 MAPK demonstrate context-dependent effects, potentially supporting either protective or detrimental outcomes depending on the timing and duration of their activation [28].

Table 1. Major Cardioprotective Signaling Pathways and Their Functions

Pathway	Components	Primary Functions	Clinical Significance
RISK	PI3K/Akt, ERK1/2	Cell survival, anti-apoptosis	Target for pharmacological interventions
SAFE	JAK/STAT3, TNF-α	Inflammation regulation, cell protection	Important in preconditioning
PKC	PKC-ε, PKC-δ	Signal transduction, ion channel regulation	Mediates preconditioning effects
NO/cGMP	eNOS, sGC, PKG	Vasodilation, platelet inhibition	Target for NO donors and PDE inhibitors
mTOR	mTORC1, mTORC2	Protein synthesis, autophagy regulation	Metabolic modulation

During ischemia-reperfusion, MAPK signaling modulates crucial cellular processes including inflammation, apoptosis, and cellular adaptation [29]. The cardioprotective effects of MAPK activation involve enhancement of anti-apoptotic protein expression, regulation of calcium homeostasis, modulation of mitochondrial function, and control of inflammatory mediator production [30].



Figure 2. Molecular Signaling Cascade in Cardioprotection

2.2.3. Sirtuins

Sirtuins, NAD+-dependent deacetylases, have emerged as critical regulators of cardiovascular health [31]. Among the seven mammalian sirtuins (SIRT1-7), SIRT1, SIRT3, and SIRT6 demonstrate particular significance in cardiac function [32]. SIRT1 activation enhances stress resistance through deacetylation of key transcription factors, including p53, FOXO, and PGC-1α [33]. This results in improved mitochondrial function, reduced oxidative stress, and enhanced cellular survival mechanisms.

SIRT3, localized primarily in mitochondria, regulates crucial metabolic enzymes and antioxidant responses [34]. Its activation promotes efficient energy metabolism and reduces oxidative damage during cardiac stress [35]. The cardioprotective effects of sirtuins encompass regulation of energy metabolism, enhancement of antioxidant defenses, modulation of inflammatory responses, and protection against age-related cardiac dysfunction [36].

2.2.4. HIF-1a Pathway

Hypoxia-Inducible Factor 1α (HIF-1α) serves as a master regulator of cellular adaptation to oxygen deprivation [37]. In cardiac tissue, HIF-1α activation triggers multiple adaptive responses through various mechanisms [38]. These responses include angiogenesis promotion through VEGF induction, metabolic reprogramming toward glycolysis, enhancement of cellular survival mechanisms, and regulation of inflammatory responses.

During ischemic conditions, HIF-1α stabilization initiates a protective genetic program that includes upregulation of glucose transporters, glycolytic enzymes, and angiogenic factors [39]. The cardioprotective effects of HIF-1α extend beyond acute responses, influencing long-term cardiac remodeling and adaptation to chronic stress [40].

2.3. Autophagy in Cardioprotection

Autophagy represents a crucial cellular quality control mechanism that maintains cardiac homeostasis under both physiological and pathological conditions [41]. During ischemia, autophagy activation serves as an adaptive response, promoting cell survival through multiple mechanisms [42]. These mechanisms include the removal of damaged organelles, recycling of cellular components, preservation of energy homeostasis, and reduction of oxidative stress. The regulation of autophagy in cardiac tissue involves multiple signaling pathways, including AMPK, mTOR, and various stress-responsive elements [43]. The beneficial effects of autophagy in cardioprotection depend critically on the timing and magnitude of its activation, with both insufficient and excessive autophagy potentially leading to adverse outcomes [44].

2.4. Oxidative Stress and Antioxidant Mechanisms

Oxidative stress plays a central role in the pathogenesis of ischemic heart disease and represents a critical target for cardioprotective interventions [45]. The imbalance between reactive oxygen species (ROS) generation and antioxidant defense mechanisms leads to cellular damage through multiple pathways. During ischemia-reperfusion, the sudden restoration of oxygen supply triggers an overwhelming production of ROS, primarily from mitochondrial sources, leading to oxidative modification of cellular proteins, lipids, and nucleic acids [46].

The cardiac tissue employs several endogenous antioxidant systems to combat oxidative stress. These systems include enzymatic antioxidants such as superoxide dismutase (SOD), catalase, and glutathione peroxidase, as well as non-enzymatic antioxidants including glutathione, vitamin C, and vitamin E [47]. The coordinated action of these systems maintains redox homeostasis under physiological conditions and becomes particularly crucial during periods of oxidative stress.

Mitochondrial dysfunction represents a major source of oxidative stress in cardiac tissue. The electron transport chain, particularly complexes I and III, generates significant amounts of superoxide radicals during ischemia-reperfusion [48]. The accumulation of these reactive species triggers a cascade of events leading to MPTP opening, calcium overload, and ultimately, cell death. The preservation of mitochondrial function through targeting of specific antioxidant mechanisms has emerged as a promising therapeutic strategy [49].

3. Pharmacological Interventions

3.1. Statins

Statins represent a cornerstone in cardiovascular pharmacotherapy, extending beyond their primary role in cholesterol reduction [50]. These agents exhibit pleiotropic effects that contribute significantly to cardioprotection. Through inhibition of HMG-CoA reductase, statins modulate various cellular signaling pathways involved in inflammation, oxidative stress, and endothelial function [51]. The cardioprotective mechanisms of statins involve multiple pathways. They enhance nitric oxide bioavailability through upregulation of endothelial nitric oxide synthase (eNOS), reduce inflammation through inhibition of pro-inflammatory cytokines, and attenuate oxidative stress through modulation of NADPH oxidase activity [52]. Additionally, statins stabilize atherosclerotic plaques through reduction of matrix metalloproteinase expression and enhancement of collagen content [53].

Recent evidence suggests that statins also influence cellular survival pathways directly relevant to cardioprotection. They activate the PI3K/Akt pathway, leading to enhanced cell survival and reduced apoptosis during ischemic stress [54]. Furthermore, statins demonstrate beneficial effects on mitochondrial function and cellular energy metabolism, contributing to their overall cardioprotective profile [55].

3.2. ACE Inhibitors

Angiotensin-Converting Enzyme (ACE) inhibitors play a vital role in cardiovascular protection through multiple mechanisms [56]. Their primary action involves the inhibition of the renin-angiotensin-aldosterone system (RAAS), but their cardioprotective effects extend beyond blood pressure regulation [57].

ACE inhibitors exert cardioprotective effects through modulation of both hemodynamic and non-hemodynamic pathways [58]. They improve endothelial function by increasing bradykinin levels and nitric oxide production, reduce oxidative stress through decreased angiotensin II formation, and attenuate cardiac remodeling by limiting fibroblast activation and collagen deposition [59].

These agents also demonstrate significant anti-inflammatory properties, reducing the expression of adhesion molecules and pro-inflammatory cytokines in vascular tissue [60].

Table 2. Comparison of Various Pharmacological Interventions

Drug Class	Mechanism of Action	Cardioprotective Effects	Limitations
Statins	HMG-CoA reductase inhibition	Pleiotropic effects, anti-inflammatory	Muscle-related side effects
Beta-blockers	β-adrenergic antagonism	Reduced oxygen demand, anti-arrhythmic	Bronchospasm, fatigue
ACE inhibitors	RAAS inhibition	Reduced remodeling, improved endothelial function	Cough, angioedema
P2Y12 inhibitors	Platelet inhibition	Antithrombotic, direct cardioprotection	Bleeding risk
GLP-1 agonists	Metabolic modulation	Improved glucose handling, direct protection	Gastrointestinal effects

3.3. Beta-Blockers

Beta-adrenergic receptor antagonists constitute a fundamental class of cardioprotective agents, operating through multiple mechanisms to preserve cardiac function [61]. Their primary action involves the antagonism of sympathetic nervous system activation, which becomes particularly important during periods of cardiac stress [62].

Beyond their chronotropic and inotropic effects, beta-blockers demonstrate significant cardioprotective properties through several mechanisms. They reduce myocardial oxygen demand, improve coronary perfusion through prolongation of diastole, and modulate calcium handling in cardiac myocytes [63]. Recent evidence indicates that beta-blockers also influence cellular signaling pathways involved in cardiac remodeling and cell survival [64]. The antiarrhythmic properties of beta-blockers contribute significantly to their cardioprotective effects. By stabilizing electrical activity in cardiac tissue and reducing the impact of catecholamines, these agents decrease the likelihood of life-threatening arrhythmias during acute ischemic events [65].



Figure 3. Cardioprotective Interventions

3.4. Antiplatelet Agents

Antiplatelet therapy represents a crucial component of cardioprotection, particularly in the context of acute coronary syndromes and secondary prevention [66]. These agents operate through various mechanisms to prevent thrombotic events and maintain vascular patency. Aspirin, the cornerstone of antiplatelet therapy, irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and subsequent platelet aggregation [67]. P2Y12 receptor antagonists, including clopidogrel, prasugrel, and ticagrelor, provide complementary antiplatelet effects through inhibition of ADP-mediated platelet activation [68].

Recent research has revealed that certain antiplatelet agents possess direct cardioprotective properties beyond their antithrombotic effects. Particularly, P2Y12 receptor antagonists have demonstrated the ability to reduce infarct size through mechanisms similar to ischemic conditioning, involving the activation of protective cellular signaling pathways [69].

3.5. Gene Therapy

Gene therapy has emerged as a promising frontier in cardioprotection, offering the potential for targeted and sustained therapeutic effects [70]. This approach involves the delivery of genetic material to cardiac tissue to modify cellular function and enhance protective mechanisms. Various vector systems, including adeno-associated viruses (AAV) and lentiviruses, have been developed for cardiac gene delivery [71, 72]

Specific gene therapy strategies focus on the overexpression of protective factors such as heat shock proteins, antioxidant enzymes, and anti-apoptotic proteins [73]. Additionally, novel approaches targeting microRNA regulation and gene editing technologies show promise in enhancing cardiac resilience to ischemic injury [74].

Table 3. Recent Therapeutic Advances in Cardioprotection

Approach	Development Stage	Mechanism	Potential Applications
Gene Therapy	Clinical trials	AAV-mediated gene delivery	Heart failure, ischemic heart disease
Cell Therapy	Phase II/III trials	Paracrine effects, regeneration	Post-MI remodeling
Exosomes	Preclinical	Signal molecule transfer	Acute cardioprotection
miRNA-based	Early clinical	Gene expression regulation	Various cardiac conditions
CRISPR/Cas9	Preclinical	Genetic modification	Inherited cardiac conditions

4. Non-Pharmacological Interventions

4.1. Exercise and Physical Activity

Regular physical activity induces profound adaptations in cardiac tissue that enhance its resistance to ischemic injury [75]. These adaptations occur at multiple levels, from molecular signaling pathways to structural modifications of the coronary vasculature. Exercise training activates numerous cardioprotective mechanisms, involving changes in mitochondrial function, antioxidant capacity, and inflammatory responses [76].

The molecular basis of exercise-induced cardioprotection involves activation of various signaling cascades. Physical activity stimulates the production of nitric oxide, enhances expression of heat shock proteins, and modifies cellular metabolism to improve energy efficiency [77]. Regular exercise also promotes the development of coronary collateral vessels, improving myocardial perfusion and reducing the impact of ischemic events [78]. Exercise training induces beneficial changes in cardiac autonomic regulation, reducing sympathetic tone and enhancing parasympathetic influence on cardiac function [79]. These adaptations contribute to improved heart rate variability and reduced susceptibility to arrhythmias during ischemic stress.

Table 4. Non-pharmacological Cardioprotective Interventions

Intervention	Primary Mechanisms	Recommended Protocol	Expected Benefits
Exercise Training	↑NO bioavailability, ↑HSP expression	150 min/week moderate intensity	30-40% reduction in CV events
Mediterranean Diet	Antioxidant effects, lipid modification	Daily olive oil, nuts, vegetables	25-30% reduction in CV events
Stress Management	↓Sympathetic activation	20 min/day meditation or relaxation	15-20% reduction in CV events
Weight Management	↓Inflammation, improved metabolism	5-10% weight reduction	20-25% reduction in CV risk
Sleep Optimization	Autonomic balance, metabolic regulation	7-9 hours/night	10-15% reduction in CV risk

4.2. Dietary Interventions

Nutritional strategies play a vital role in cardiovascular protection through multiple mechanisms [80]. The Mediterranean dietary pattern, characterized by high consumption of fruits, vegetables, whole grains, and omega-3 rich foods, demonstrates significant cardioprotective effects [81]. This dietary approach influences various aspects of cardiovascular health, including lipid profiles, inflammatory markers, and endothelial function.

Specific dietary components exhibit direct cardioprotective properties. Polyphenols, found abundantly in fruits, vegetables, and olive oil, demonstrate antioxidant and anti-inflammatory effects [82]. Omega-3 fatty acids, particularly EPA and DHA, modulate membrane fluidity, reduce inflammation, and influence cardiac electrical properties [83]. Plant-based proteins and fiber contribute to improved lipid profiles and reduced inflammation [84].

4.3. Stress Management

Psychological stress significantly impacts cardiovascular health through multiple pathophysiological mechanisms [85]. Chronic stress activation of the sympathetic nervous system and hypothalamic-pituitary-adrenal axis contributes to cardiovascular risk through effects on blood pressure, inflammation, and metabolic function [86]. Various stress reduction techniques, including meditation, mindfulness practices, and structured relaxation programs, demonstrate beneficial effects on cardiovascular parameters [87]. These interventions reduce sympathetic activation, improve heart rate variability, and modify inflammatory markers associated with cardiovascular risk [88].

4.4. Smoking Cessation

Tobacco cessation represents a crucial intervention in cardiovascular protection [89]. Smoking causes endothelial dysfunction, increases oxidative stress, and promotes inflammatory responses in vascular tissue [90]. Cessation of smoking rapidly improves several cardiovascular parameters, including endothelial function and inflammatory markers [91]. The mechanisms underlying the cardiovascular benefits of smoking cessation involve multiple pathways. These include improved nitric oxide bioavailability, reduced oxidative stress, enhanced endothelial repair mechanisms, and modified platelet function [92]. The benefits of smoking cessation become apparent within weeks of discontinuation and continue to accrue over time [93].

4.5. Weight Management

Optimal weight management serves as a fundamental component of cardiovascular protection, particularly given the strong association between obesity and cardiovascular risk [94]. Adipose tissue functions as an active endocrine organ, secreting various bioactive molecules that influence cardiovascular function and metabolism [95]. Weight reduction through structured programs improves multiple cardiovascular parameters. These improvements manifest through decreased inflammatory markers, enhanced insulin sensitivity, reduced oxidative stress, and improved endothelial function [96]. Furthermore, weight management positively influences cardiac structure and function, reducing left ventricular mass and improving diastolic function [97]. The molecular mechanisms underlying the cardiovascular benefits of weight management include modifications in adipokine profiles, reduced activation of the renin-angiotensin-aldosterone system, and improved mitochondrial function in cardiac tissue [98]. Sustained weight management also contributes to enhanced effectiveness of other cardioprotective interventions [99].

5. Combination approaches

The complexity of ischemic heart disease necessitates a multi-faceted approach to cardioprotection, integrating pharmacological and non-pharmacological strategies [100]. This integrated approach acknowledges the interconnected nature of various protective mechanisms and the potential for synergistic effects among different interventions. Molecular pathways activated by different cardioprotective strategies often overlap and interact, creating opportunities for enhanced protection through combined approaches [101]. For instance, exercise training may amplify the benefits of pharmacological interventions through shared effects on cellular signaling pathways [102]. Similarly, dietary modifications may enhance the effectiveness of antithrombotic therapy through complementary effects on platelet function and vascular health [103]. The timing and sequence of cardioprotective interventions also merit consideration. Early implementation of preventive strategies, combined with appropriate acute interventions during ischemic events, provides optimal protection [104]. Long-term maintenance of cardioprotective measures requires sustained engagement with both pharmacological and lifestyle interventions [105].

6. Conclusion

The interrelationship between various protective pathways shows the importance of considering multiple intervention approaches in preventing and treating ischemic heart disease. Recent literature in molecular cardiology have shown new targets for therapeutic intervention, while confirming the significance of established protective mechanisms. The development of gene therapy and targeted molecular approaches offers promising directions for future therapeutic development. The success of cardioprotective interventions ultimately depends on the integration of scientific knowledge with practical clinical application. This combination must consider individual patient characteristics, timing of interventions, and the interaction between various protective mechanisms.

References

[1] Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528.

[2] Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92-100.

[3] Stone GW, Hochman JS, Williams DO, et al. Clinical outcomes following long-term coronary artery disease management. N Engl J Med. 2021;384(13):1208-1220.

[4] Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337.

[5] Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. J Am Coll Cardiol. 2014;64(22):e77-e137.

[6] Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases. Eur Heart J. 2018;39(9):763-816.

[7] Davidson SM, Ferdinandy P, Andreadou I, et al. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury. J Am Coll Cardiol. 2019;73(1):89-99.

[8] Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015;116(4):674-699.

[9] Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65(14):1454-1471.

[10] Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124-1136.

[11] Cohen MV, Downey JM. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. 2015;172(8):1913-1932.

[12] Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121-1135.

[13] Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004;61(3):448-460.

[14] Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88(2):581-609.

[15] Bolli R. The late phase of preconditioning. Circ Res. 2000;87(11):972-983.

[16] Yin C, Salloum FN, Kukreja RC. A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res. 2009;104(5):572-575.

[17] Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285(2):H579-H588.

[18] Vinten-Johansen J, Shi W. The science and clinical translation of remote postconditioning. J Cardiovasc Med. 2013;14(3):206-213.

[19] Hausenloy DJ, Barrabes JA, Bøtker HE, et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016;111(6):70.

[20] Halestrap AP, Richardson AP. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol. 2015;78:129-141

[21] Rossello X, Yellon DM. The RISK pathway and beyond. Basic Res Cardiol. 2018;113(1):2.

[22] Hausenloy DJ, Garcia-Dorado D, Bøtker HE, et al. Novel targets and future strategies for acute cardioprotection. Cardiovasc Res. 2017;113(11):1338-1349.

[23] Fujio Y, Nguyen T, Wencker D, et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101(6):660-667.

[24] Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113(11):1535-1549.

[25] Matsui T, Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol. 2005;38(1):63-71.

[26] Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010;90(4):1507-1546.

[27] Muslin AJ. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond). 2008;115(7):203-218.

[28] Lip GYH, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future. Thromb Haemost. 2017;117(7):1230-1239.

[29] Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol. 2005;14(4):170-175.

[30] Baines CP. How and when do myocytes die during ischemia and reperfusion: the late phase. J Cardiovasc Pharmacol Ther. 2011;16(3-4):239-243.

[31] Hsu CP, Zhai P, Yamamoto T, et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation. 2010;122(21):2170-2182.

[32] Pillai VB, Sundaresan NR, Gupta MP. Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging. Circ Res. 2014;114(2):368-378.

[33] Yamamoto T, Sadoshima J. Protection of the heart against ischemia/reperfusion by silent information regulator 1. Trends Cardiovasc Med. 2011;21(1):27-32.

[34] Sundaresan NR, Gupta M, Kim G, et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009;119(9):2758-2771

[35] Koentges C, Pfeil K, Schnick T, et al. SIRT3 deficiency impairs mitochondrial and contractile function in the heart. Basic Res Cardiol. 2015;110(4):36.

[36] Matsushima S, Sadoshima J. The role of sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol. 2015;309(9):H1375-H1389.

[37] Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 2014;76:39-56.

[38] Ong SG, Hausenloy DJ. Hypoxia-inducible factor as a therapeutic target for cardioprotection. Pharmacol Ther. 2012;136(1):69-81.

[39] Lee SH, Wolf PL, Escudero R, et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000;342(9):626-633.

[40] Feinberg MW, Moore KJ. MicroRNA regulation of atherosclerosis. Circ Res. 2016;118(4):703-720.

[41] Gustafsson ÅB, Gottlieb RA. Autophagy in ischemic heart disease. Circ Res. 2009;104(2):150-158.

[42] Sciarretta S, Maejima Y, Zablocki D, Sadoshima J. The role of autophagy in the heart. Annu Rev Physiol. 2018;80:1-26.

[43] Lavandero S, Chiong M, Rothermel BA, Hill JA. Autophagy in cardiovascular biology. J Clin Invest. 2015;125(1):55-64.

[44] Przyklenk K, Dong Y, Undyala VV, Whittaker P. Autophagy as a therapeutic target for ischaemia/reperfusion injury? Concepts, controversies, and challenges. Cardiovasc Res. 2012;94(2):197-205.

[45] Granger DN, Kvietys PR. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol. 2015;6:524-551.

[46] Murphy E, Ardehali H, Balaban RS, et al. Mitochondrial function, biology, and role in disease: a scientific statement from the American Heart Association. Circ Res. 2016;118(12):1960-1991.

[47] Santos CX, Anilkumar N, Zhang M, et al. Redox signaling in cardiac myocytes. Free Radic Biol Med. 2011;50(7):777-793.

[48] Brown DA, Perry JB, Allen ME, et al. Mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2017;14(4):238-250.

[49] Cadenas S. ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic Biol Med. 2018;117:76-89.

[50] Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229-243.

[51] Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203(2):325-330.

[52] Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37-44.

[53] Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):III39-III43.

[54] Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003;41(3):508-515.

[55] Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.

[56] Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98(1):121-128.

[57] Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125-1135.

[58] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.

[59] Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90(4):2056-2069.

[60] Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37(4):1047-1052.

[61] López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341-1362.

[62] Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet. 2003;362(9377):7-13.

[63] Opie LH, Gersh BJ. Beta-blocking agents. In: Drugs for the Heart. 8th ed. Philadelphia: Elsevier Saunders; 2013:1-37.

[64] Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994;23(3):814-821.

[65] Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57(12):43F-49F.

[66] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease. Eur Heart J. 2018;39(3):213-260.

[67] Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373-2383.

[68] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.

[69] Cohen MV, Downey JM. Combined cardioprotective effects of ischemic preconditioning and adenosine-enhancing therapy. Basic Res Cardiol. 2016;111(3):35.

[70] Hajjar RJ. Potential of gene therapy as a treatment for heart failure. J Clin Invest. 2013;123(1):53-61.

[71] Wolfram JA, Donahue JK. Gene therapy to treat cardiovascular disease. J Am Heart Assoc. 2013;2(4):e000119.

[72] Zsebo K, Yaroshinsky A, Rudy JJ, et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014;114(1):101-108.

[73] Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest. 2013;123(1):11-18.

[74] Dimmeler S, Zeiher AM. Cardiac regeneration and rejuvenation: the promise of stem cell therapy. J Am Coll Cardiol. 2014;63(25 Pt A):2938-2940

[75] Lavie CJ, Arena R, Swift DL, et al. Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ Res. 2015;117(2):207-219.

[76] Powers SK, Sollanek KJ, Wiggs MP, et al. Exercise-induced improvements in myocardial antioxidant capacity: the antioxidant players and cardioprotection. Free Radic Res. 2014;48(1):43-51.

[77] Golbidi S, Laher I. Exercise and the cardiovascular system. Cardiol Res Pract. 2012;2012:210852.

[78] Laughlin MH, Bowles DK, Duncker DJ. The coronary circulation in exercise training. Am J Physiol Heart Circ Physiol. 2012;302(1):H10-H23.

[79] Thijssen DHJ, Redington A, George KP, et al. Association of exercise preconditioning with immediate cardioprotection: A review. JAMA Cardiol. 2018;3(2):169-176.

[80] Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279-1290.

[81] Martinez-Gonzalez MA, Bes-Rastrollo M. Dietary patterns, Mediterranean diet, and cardiovascular disease. Curr Opin Lipidol. 2014;25(1):20-26.

[82] Del Rio D, Rodriguez-Mateos A, Spencer JP, et al. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal. 2013;18(14):1818-1892.

[83] Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047-2067.

[84] Anderson JW, Baird P, Davis RH Jr, et al. Health benefits of dietary fiber. Nutr Rev. 2009;67(4):188-205.

[85] Steptoe A, Kivimäki M. Stress and cardiovascular disease: an update on current knowledge. Annu Rev Public Health. 2013;34:337-354.

[86] Dar T, Radfar A, Abohashem S, et al. Psychosocial stress and cardiovascular disease. Curr Treat Options Cardiovasc Med. 2019;21(5):23.

[87] Nijjar PS, Puppala VK, Dickinson O, et al. Modulation of the autonomic nervous system through mind and body practices as a treatment for atrial fibrillation. Rev Cardiovasc Med. 2019;20(3):129-137.

[88] Younge JO, Gotink RA, Baena CP, et al. Mind-body practices for patients with cardiac disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(11):1385-1398.

[89] Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1):86-97.

[90] Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509-515.

[91] Johnson HM, Gossett LK, Piper ME, et al. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol. 2010;55(18):1988-1995.

[92] Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol. 2013;10(4):219-230.

[93] Benowitz NL, Burbank AD. Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. Trends Cardiovasc Med. 2016;26(6):515-523.

[94] Lavie CJ, De Schutter A, Parto P, et al. Obesity and prevalence of cardiovascular diseases and prognosis-the obesity paradox updated. Prog Cardiovasc Dis. 2016;58(5):537-547.

[95] Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97.

[96] Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486.

[97] Alpert MA, Lavie CJ, Agrawal H, et al. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management. Transl Res. 2014;164(4):345-356.

[98] Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875-880.

[99] Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014;129(25 Suppl 2):S102-S138.

[100] Hausenloy DJ, Yellon DM. Targeting myocardial reperfusion injury--the search continues. N Engl J Med. 2015;373(11):1073-1075

[101] Heusch G, Libby P, Gersh B, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383(9932):1933-1943.

[102] Hambrecht R, Adams V, Erbs S, et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. 2003;107(25):3152-3158.

[103] Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.

[104] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177.

[105] Davidson SM, Takov K, Yellon DM. Exosomes and cardiovascular protection. Cardiovasc Drugs Ther. 2017;31(1):77-86